- Pyroptosis is a highly inflammatory form of programmed cell death characterised by cell swelling, membrane rupture, and the release of pro‑inflammatory cytokines. Unlike apoptosis, which is non‑inflammatory and tightly controlled, pyroptosis triggers strong immune activation and is primarily associated with microbial infections and innate immune responses. It is driven by the activation of inflammatory caspases and the formation of membrane pores by gasdermin proteins. Pyroptosis plays a central role in innate immunity, host defence, and inflammatory disease.
- Pyroptosis is initiated by the activation of inflammasomes, multiprotein complexes that detect pathogenic microorganisms, toxins, or cellular stress. The best‑studied inflammasome is the NLRP3 inflammasome, which responds to diverse stimuli such as ATP, pore‑forming toxins, and crystalline substances. Upon activation, inflammasomes recruit and activate caspase‑1, the central enzyme responsible for processing pro‑inflammatory cytokines and initiating pyroptotic cell death. Other inflammasomes, such as AIM2 and NLRC4, respond to cytosolic DNA or bacterial flagellin, respectively, highlighting the versatility of pyroptotic signalling.
- Activated caspase‑1 cleaves the precursor forms of interleukin‑1β (IL‑1β) and interleukin‑18 (IL‑18), converting them into mature cytokines that are released during cell lysis. Caspase‑1 also cleaves gasdermin D (GSDMD), producing an N‑terminal fragment that inserts into the plasma membrane to form large pores. These pores disrupt ionic gradients, cause cell swelling, and ultimately lead to membrane rupture. The release of cytokines and intracellular contents amplifies inflammation and recruits additional immune cells to the site of infection.
- Pyroptosis can also be triggered through non‑canonical pathways involving caspase‑4 and caspase‑5 in humans (and caspase‑11 in mice). These caspases directly sense cytosolic lipopolysaccharide (LPS) from Gram‑negative bacteria, bypassing inflammasome activation. Once activated, they cleave gasdermin D and induce pyroptosis. This pathway provides a rapid defence mechanism against intracellular pathogens and complements canonical inflammasome signalling.
- Pyroptosis plays a crucial role in host defence by eliminating infected cells and exposing pathogens to extracellular immune mechanisms. The release of IL‑1β and IL‑18 promotes fever, neutrophil recruitment, and activation of adaptive immunity. Pyroptosis also enhances antigen presentation by releasing intracellular antigens that can be processed by dendritic cells. In this way, pyroptosis bridges innate and adaptive immune responses.
- However, excessive or dysregulated pyroptosis contributes to inflammatory and autoimmune diseases. Overactivation of inflammasomes is implicated in conditions such as gout, atherosclerosis, type 2 diabetes, Alzheimer’s disease, and inflammatory bowel disease. Chronic pyroptotic signalling can lead to tissue damage, fibrosis, and metabolic dysfunction. Understanding how pyroptosis is regulated provides insight into the mechanisms underlying these disorders.
- Therapeutically, targeting pyroptosis is an emerging strategy in inflammatory disease and infection. Inhibitors of NLRP3, caspase‑1, and gasdermin D are being explored to reduce excessive inflammation. Conversely, inducing pyroptosis in cancer cells is a promising approach for immunotherapy, as pyroptotic tumour cells release danger signals that activate anti‑tumour immunity. These dual roles highlight pyroptosis as both a protective and pathological process.
- Overall, pyroptosis is a specialised form of inflammatory cell death essential for immune defence and pathogen clearance. Its reliance on inflammasomes, caspases, and gasdermin pores makes it a unique and powerful mechanism for controlling infection and shaping immune responses. Understanding pyroptosis provides valuable insight into inflammation, immunity, and therapeutic innovation.
